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Abstract
Equol, a microbial metabolite of daidzein, has been hypothesized as a clue to the effectiveness of soy and its isoflavones
but is excreted by only 33% of Caucasians. Microbial and dietary factors associated with the ability to harbor equol-
producing bacteria were studied in a randomized dietary intervention trial with 100 healthy postmenopausal women. After
a 4-d baseline period, subjects delivered first-void urine, fecal, and breath samples. During the 5-d treatment period, 3
portions of either soymilk or soy germ containing 28.51 and 37.99 mg isoflavone aglycone equivalents/portion,
respectively, were administered daily, and on the last day, 24-h urine samples were collected. The urinary recoveries of
genistein and daidzein from soymilk were significantly higher than those from soy germ tablets. Because the proportion of
equol:(daidzein 1 metabolites) in the urine did not differ between the treatment groups, subjects were pooled and
classified into poor, moderate, and strong equol producers based on this criterion. The strong equol producer phenotype
correlated negatively [in vivo, r¼20.478 (20.256 to20.893), P¼ 0.021; in vitro, r¼20.576 (20.350 to20.949), P¼ 0.030]
with Clostridium coccoides-Eubacterium rectale counts and positively [in vivo, r¼ 1.158 (0.971–1.380), P¼ 0.048; in vitro,
r ¼ 1.156 (1.007–1.327), P ¼ 0.039] with the abundance of sulfate-reducing bacteria. Furthermore, persons with a higher
PUFA [in vivo, r ¼ 2.150 (1.058–4.371), P ¼ 0.034; in vitro, r ¼ 2.131 (1.144–3.967), P ¼ 0.017] and alcohol [in vivo,
r¼ 1.166 (0.721–1.887), P¼ 0.050; in vitro, r¼ 1.850 (1.215–2.817), P¼ 0.004] intake were more likely to be strong equol
producers. Finally, we validated the daidzein metabolism by fecal cultures as screening assay to identify equol producers
without dietary intervention. J. Nutr. 137: 2242–2246, 2007.
Introduction
Considering the results of the Women’s Health Initiative (1) and
the Million Women Study (2), the North American Menopause
Society recommends lifestyle-related strategies and nonprescrip-
tion remedies such as dietary isoflavones for the relief of mild
menopause-associated vasomotor symptoms prior to prescribing
systemic estrogen-containing products (3). Isoflavones are weak
agonists of the estrogen receptors; in vitro they have a higher
affinity to estrogen receptor-b than -a (4) and are, therefore,
often regarded as natural selective estrogen receptor modulators.
High levels of isoflavones are found in traditional soy-based
foods, soy protein isolate, soy concentrate, and soy flour as well
as in dietary supplements that are now widely available.
Although isoflavone ingestion results in increased levels of
the parent isoflavones in plasma and urine, these compounds can
also be metabolized. The importance of the gut microbiota in the
metabolism of isoflavones has been convincingly demonstrated
in in vitro and in vivo studies (5). Firstly, because isoflavones
derived from our food occur mainly as glycosides, their intestinal
absorption requires deglycosylation (6). b-Glucosidases of both
the intestinal mucosa and the gut microbiota are involved in this
hydrolysis (7,8). Secondly, these bioactive aglycones are extensively
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conjugated during and after absorption through the gut barrier
(6). Bacterial enzymes can deconjugate the glucuronides and
sulfate esters excreted in the bile and, consequently, enhance the
reuptake of isoflavones (5). Finally, specific microbial trans-
formation reactions occur in the colon. Genistein can be con-
verted to dihydrogenistein and 6#-hydroxy-O-desmethylangolensin
or 2,4,6-trihydroxybenzoic acid and p-ethyl phenol, whereas
the major microbial metabolites of daidzein are dihydrodaidzein
(DHD),11 equol, and O-desmethylangolensin (O-DMA). The
extent of this microbial metabolism varies considerably among
individuals (9,10).
Equol has gained much attention since the postulation of the
equol hypothesis, contending a greater efficacy of soy food diets
in so-called equol producers (11). Equol is exclusively formed by
intestinal microbiota and only 33% of Caucasians are host to a
population of intestinal microorganisms capable of converting
daidzein into equol (12). Yet, factors influencing the bioactiva-
tion of daidzein in vivo remain unclear. Besides the composition
and activity of the intestinal microbiota, the diet has been
suggested to contribute to the ability to harbor equol-producing
bacteria. More in particular, differences in total fat and/or
dietary fiber consumption have been highlighted in previous
studies (9,10,13,14), but the results are contradictory.
The purpose of this work was to: 1) compare the urinary
excretion of soy-derived isoflavones and metabolites after
consumption of soymilk and soy germ tablets; 2) evaluate the
performance of in vitro incubations as an equol-producer
phenotyping assay; and 3) identify microbial and dietary factors
associated with equol production. Therefore, a randomized
dietary intervention trial with 100 healthy postmenopausal
Caucasian women was conducted.
Study Design and Methods
Chemicals. Analytical standards for genistein and daidzein, for equol,
and for DHD and O-DMA were purchased from Sigma-Aldrich,
Extrasynthe`se, and Plantech UK, respectively. SoyLife EXTRA, a soy
germ powder containing 32.4 mg daidzein/g, was kindly provided by
Frutarom Netherlands BV. Type H-1 Helix pomatia extract (min. 300 U
b-glucuronidase/mg and 15.3 U sulfatase/mg), p-nitrophenol, p-nitrophenyl-
b-D-glucopyranoside, and p-nitrophenyl-b-D-glucuronide were obtained
from Sigma-Aldrich.
Isoflavone preparations. The isoflavone preparations used in this
study were commercially available soymilk derived from whole soybeans
(Alpro Soya Drink Nature) in 250-mL cartons and a soy germ powder
(SoyLife EXTRA) formulated as tablets. Both preparations were kindly
provided by their manufacturers.
One portion of soymilk (250 mL) contained 7.03 6 0.23 mg
glycitein, 16.16 6 0.19 mg genistein, and 5.32 6 0.08 mg daidzein
aglycone equivalents, of which 1.38, 4.43, and 4.47% were present as
aglycones, respectively. Each soy germ tablet contained 12.336 0.70 mg
glycitein, 5.18 6 0.16 mg genistein, and 20.48 6 1.04 mg daidzein
aglycone equivalents, of which 2.53, 2.07, and 2.46%, respectively, were
not glycosylated.
Subjects. A total of 100 healthy postmenopausal ($1 y since last
menses) Caucasian women aged 44–76 y (57 6 6 y) participated in this
study. Their mean BMI based on self-reported weight and height
measurements was 23.96 3.7 kg/m2. The exclusion criteria were the use
of any exogenous hormone medications, use of antibiotics within the
previous month, soy allergy, and a history of gastrointestinal diseases or
cancer. Ten participants had taken antibiotics 1–3 mo prior to the study,
7 and 12 subjects finished their last treatment 3–6 mo and 6–12 mo
before recruitment, and 71 women did not use antibiotics during the
previous year.
Study design. This study was a randomized dietary intervention trial
with a baseline period of at least 4 d and a treatment with soymilk or soy
germ tablets during 5 d. Participants consumed their habitual western-
type diets but were asked to abstain from soy-based products during the
trial. A detailed list of isoflavone-containing foods and dietary supple-
ments was distributed to guide the volunteers in this respect. After the
baseline period, subjects delivered first-void urine, fecal, and breath
samples. During the treatment period, 3 portions of either soymilk or soy
germ were taken daily. On the last day, a 24-h urine sample was
collected.
A validated self-administered semiquantitative FFQ was used to
estimate the usual fat [total fat, SFA, monounsaturated fatty acid
(MUFA) and PUFA], fiber, alcohol, caffeine, and theobromine intake
(15). In addition, a general questionnaire including questions about
medication use; intake of pre-, pro-, and synbiotics; reproductive factors;
sociodemographics; and anthropometric measures was administered.
Sample collection and processing. End-expiratory breath samples
were collected using the QuinTron GaSampler system (Ecce Medical)
and analyzed immediately by GC-flame ionisation detector (15). The
background room air was found to contain ,2 ppm methane. Partic-
ipants were considered to be methane producers (61%) when their
breath methane concentration exceeded 3 ppm (16).
Volumes of the 24-h urine samples were measured and aliquots were
stored at –20C. For the hydrolysis of conjugated isoflavones, a 33-g/L
solution of Type H-1 Helix pomatia extract in sodium acetate buffer
(0.1 mol/L, pH 5) was prepared. One milliliter urine was added to 1 mL
sodium acetate buffer and 20 mL b-glucuronidase/arylsulfatase solution
and incubated for 1 h at 37C. The hydrolyzed samples were spiked with
90 mL internal standard (0.4 mol/L 4-hydroxybenzophenone in ethyl
acetate) and extracted twice with 5 mL diethyl ether. Finally, the solvent
was evaporated at room temperature under a gentle stream of N2 and the
residue was dissolved in 200 mL methanol, transferred into vials, and
stored at 220C prior to HPLC analysis.
The participants were supplied with plastic containers and asked to
bring their samples as soon as possible after defecation. Within 6 h of
collection, fecal suspensions were prepared by homogenizing 20 g feces
with 100 mL phosphate buffer (0.5 mol/L, pH 7) supplemented with
1 g/L sodium thioglycolate. Particulate material was removed by centrifu-
gation at 400 3 g; 2 min. To assess the daidzein metabolism, fecal
cultures were incubated anaerobically for 3 d at 37C with 4 g/L SoyLife
EXTRA in Brain Heart Infusion broth (37 g/L, Oxoid) supplemented
with 0.5 g/L L-cystein HCl and 2 mg/L resazurin, as described Possemiers
et al. (17).
Chromatographic methods. Methane concentrations in the alveolar
air samples were measured with a Chrompack CP 9000 GC equipped
with flame ionization detector (Chrompack) and a NaI-inactivated
alumina column (100–120 mesh, 3 mm 3 1.8 m; Alltech Ass.) (15).
Quantitative analyses of the isoflavones genistein and daidzein and
the metabolites DHD, O-DMA, and equol were performed by HPLC-
UV using a Waters 2695 Alliance separations module and 996 photo-
diode array detector (Waters) as reported by Maubach et al. (18). The
reversed-phase column was an XTerra MS C18 (5 mm, 4.6 mm 3 250
mm; Waters). UV detection was conducted at 260 nm for genistein,
248 nm for daidzein, 277 nm for O-DMA and DHD, and 230 nm for
equol. The internal standard was detected simultaneously with and at the
same wavelength as described above for each compound.
Microbiological analyses. For the assessment of b-glucosidase and
b-glucuronidase activities, fecal suspensions were centrifuged (50003 g;
5 min), diluted 5-fold in phosphate buffer (0.5 mol/L, pH 7), and
incubated aerobically for 30 min at 37C with p-nitrophenyl-b-D-
glucopyranoside (2.5 mmol/L) or p-nitrophenyl-b-D-glucuronide (2.5
mmol/L), respectively (15). The release of p-nitrophenol was recorded
with a Tecan Sunrise absorbance reader (Tecan Benelux) at 405 nm
before and after incubation.
11 Abbreviations used: DHD, dihydrodaidzein; MUFA, monounsaturated fatty
acid; O-DMA, O-desmethylangolensin.
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Total DNA from the fecal suspensions was extracted with QIAamp
DNA Stool Mini kits (Qiagen GmbH). The 16S ribosomal RNA genes
of bacteria, bifidobacteria, members of the Clostridium coccoides-
Eubacterium rectale group, dsrB genes of sulfate-reducing bacteria, and
mcrA genes of methanogens were amplified by real-time PCR using an
ABI Prism 7000 sequence detection system (PE Applied Biosystems), as
described by Possemiers et al. (17) and Van de Wiele et al. (19).
Statistical analyses. All extractions and analyses were performed in
triplicate. We used SPSS for Windows version 12.0. Unless reported
differently, results were considered significant at an a 2-tailed level of
0.05. Tests for normality of the data and equality of the variances were
performed using the Kolmogorov-Smirnov and Levene’s test, respec-
tively. Comparison of normally distributed data was performed with
Student’s t test. The nonparametric Mann-Whitney U and Kruskal-
Wallis test were used to compare means of nonnormally distributed data.
Categorical variables were analyzed using cross-tabulations with x2 or
Fisher’s exact tests. Associations were described using nonparametric
Spearman correlations.
Based on the ratios equol:(daidzein1metabolites) excreted in the
24-h urine samples and produced by the fecal cultures, subjects were
separated into significantly different groups of in vivo and in vitro
producers, respectively, using the TwoStep cluster analysis protocol.
Cross-classification analyses and weighted k statistics, calculated with a
linear set of weights (20), were used to measure the level of agreement
between the in vivo and in vitro phenotyping method. Associations
between the producer phenotypes and subject characteristics, microbial,
and dietary variables were evaluated using nominal logistic regression
with poor equol producers as reference category.
Ethics approval. Ethical approval was granted from the Ethics
Committee of the Ghent University Hospital (EC UZG 2004/044). The
volunteers were fully informed on the aims of the study and gave their
written consent.
Results
Soymilk vs. soy germ tablets. The soymilk and soy germ
groups did not differ in terms of subject characteristics, dietary
habits, breath methane excretion, microbial metabolism of
daidzein in vivo and in vitro, composition of the intestinal
microbiota, and fecal b-glucosidase and b-glucuronidase activ-
ities (Supplemental Table 1).
The sum of unconjugated forms and deconjugated glucuro-
nides and sulfates of genistein, daidzein, DHD, equol, and
O-DMA in the 24-h urine samples was quantified as daily
excretion and dose-percentages recovered (Table 1) and used as
proxy for their bioavailability. The recovery of genistein was
significantly higher in the soymilk group than the group treated
with soy germ. The mean dose-percentages of daidzein detected
in the urine differed significantly between the treatment groups
only when the daidzein metabolites DHD, equol, and O-DMA
were also taken into consideration. For genistein, a significant
positive correlation (r ¼ 0.209; P ¼ 0.038) was found between
the ingested amount and the urinary recovery, whereas a stronger
negative relation (r ¼ 20.329; P ¼ 0.001) was observed for
daidzein. Neither the fecal b-glucosidase nor the b-glucuronidase
activity correlated significantly with the recovery or excretion of
genistein and daidzein (Supplemental Tables 2 and 3).
Daidzein metabolism. Based on the percentage daidzein
aglycone equivalents excreted in the 24-h urine as equol, the
participants were classified as poor (61%), moderate (21%), and
strong (18%) in vivo equol producers, respectively. Because
almost identical classifications (weighted k, 0.96; 95% CI, 0.78;
1.14) were obtained when considering the participants of only
1 treatment group, the distinction between the soymilk and soy
germ groups was removed for the further analyses of the
daidzein metabolism. The in vitro microbial metabolism of
daidzein was highly variable, ranging from 0 to 100% daidzein
transformed into equol, which led to a separation of the subjects
in poor (51%), moderate (10%), and strong (39%) in vitro
equol producers. The in vivo and in vitro phenotyping methods
resulted in the same clustering for 65% of the subjects, whereas
10% were assigned to opposite tertiles. The weighted kwas 0.53
(95% CI, 0.37; 0.69). The ratios equol:(daidzein 1metabolites)
excreted in the 24-h urine samples and produced by the fecal
cultures correlated well (r ¼ 0.845; P , 0.001). Lower cor-
relations were obtained for the proportions daidzein:(daidzein1
metabolites) (r ¼ 0.411; P , 0.001), DHD:(daidzein 1
metabolites) (r ¼ 0.443; P , 0.001), and O-DMA:(daidzein
1 metabolites) (r ¼ 0.526; P , 0.001) in the urine and
incubation broths.
Factors associated with equol production. Age, BMI, smok-
ing, use of antibiotics, fecal b-glucosidase, and b-glucuronidase
activity and the intake of caffeine, theobromine, and pre-, pro-,
and synbiotic preparations were not significantly associated with
the ability to produce equol. However, differences in specific
microbial and dietary factors could be linked to the variation in
equol production in vivo (Table 2) and in vitro (Table 3). A
negative relation was observed between the Clostridium
coccoides-Eubacterium rectale counts and the strong in vivo
(P¼0.021) and in vitro (P¼0.030) equol producer phenotype. In
contrast, the abundance of sulfate-reducing bacteria correlated
positively with the strong in vivo (P ¼ 0.048) and in vitro (P ¼
0.039) equol producer phenotypes. There was a positive associ-
ation (P , 0.050) between the estimated usual intake of PUFA
and the production of equol. In addition, persons who reported
higher alcohol consumption were more likely to be strong in vivo
(P ¼ 0.050) and in vitro (P ¼ 0.004) equol producers.
Discussion
The bioavailability of dietary phytoestrogens such as soy
isoflavones is characterized by considerable inter-individual var-
iation, which may influence the bioactivity of these compounds
TABLE 1 Concentrations of genistein, daidzein, and its
metabolites in 24-h urine samples of





tablet (n ¼ 50) P
Excretion, mg/d
Genistein 10.09 6 0.76 2.86 6 0.32 ,0.001
Daidzein 8.20 6 0.54 28.18 6 2.28 ,0.001
DHD 1.46 6 0.18 6.76 6 0.98 ,0.001
Equol 2.81 6 0.47 7.42 6 1.77 0.943
O-DMA 1.76 6 0.26 3.01 6 0.51 0.149
Recovery,3 %
Genistein (as genistein) 20.96 6 1.57 18.42 6 2.03 0.037
Daidzein (as daidzein) 51.39 6 3.41 45.87 6 3.71 0.229
Daidzein (as daidzein 1 metabolites) 90.50 6 4.31 73.86 6 4.46 0.002
1 Values are means 6 SEM, n ¼ 50.
2 Intake of 48.48 mg genistein and 15.96 mg daidzein aglycon equivalents per day in
the soymilk group; intake of 15.54 mg genistein and 61.44 mg daidzein aglycon
equivalents per day in the soy germ group.
3 Recovery ¼ excretion in 24-h urine/daily intake.
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in humans. In this study, differences in microbial and dietary
factors could be linked to the variation in equol production in
vivo and in vitro. No isoflavones were detected at baseline, as
expected from the results of Faughnan et al. (21). The dose-
percentages of genistein and daidzein measured in the 24-h urine
samples agreed with previous reports (22,23) and were generally
higher following soymilk consumption than soy germ ingestion.
To determine whether the formulation [chemical composition,
dose, and matrix; (5)] was responsible for the difference in
daidzein and genistein recovery between the treatment groups,
interventions with fully controlled meals are needed.
In response to the need for a universal and consistent way to
phenotype individuals with low soy consumption patterns,
Setchell and Cole (24) introduced a new data processing method
to define the equol producer phenotype. Although the log10-
transformed ratio equol:daidzein excreted in the urine is
independent of the precursor intake, this method requires a
challenge with soy isoflavones. Furthermore, other daidzein
metabolites are not considered, which makes discrimination
between the profiles of person A excreting 50 units as daidzein
and 50 as equol, and person B excreting 10 units as daidzein, 80
as O-DMA, and 10 as equol, impossible. Here, we propose a
different approach to identify equol producers based on the
daidzein metabolism by fecal cultures without a dietary inter-
vention.
In this study, both the equol production and the clustering of
the subjects into poor, moderate and strong equol producers
based on the in vitro experiments correlated well with those
estimated from the urinary excretion profiles. The proportion
equol:(daidzein 1 metabolites) in the incubation broths was
generally higher than in the urine, accounting for 83% of the
cases classified in adjacent tertiles and 90% of the misclassifi-
cation. Switching to a binary system with low (i.e. poor in vivo
and poor and moderate in vitro producers) and high (i.e.
moderate and strong in vivo and strong in vitro producers) equol
producers resulted in an even better agreement (k, 0.62; 95% CI,
0.417; 0.82), with 39% high equol producers, as expected from
the literature (12). In contrast, using the formula of Setchell and
Cole (24), 61% of the subjects would be defined as high equol
producers. This discrepancy was mainly due to the contribution
of DHD and O-DMA. Although the in vivo bioavailability is the
final result of a cascade of complex processes, these results show
that 1 fecal sample is sufficient to phenotype an individual as low
or high equol producer. Moreover, the same sample could be
used to get additional information on the bioactivation of other
dietary phytoestrogens such as hop-derived prenylflavonoids
(15).
As reviewed by Atkinson et al. (12), the factors triggering the
ability to harbor equol-producing bacteria are still unknown.
Inter-individual differences in the composition of the gut
microbiota as well as the background diet have been suggested
to contribute. In this cohort, the strong equol-producer phenotype
correlated negatively with Clostridium coccoides-Eubacterium
rectale counts and positively with the abundance of sulfate-
reducing bacteria. Hydrogen gas is formed in the colon by a va-
riety of hydrolytic and saccharolytic bacteria to dispose reducing
equivalents during fermentation and is consumed by methano-
genic, homoacetogenic, and sulfate-reducing microbiota. Decroos
et al. (25) highlighted the importance of H2 in the production of
equol, but further research is needed to explain this interaction.
Several studies reported differences in total fat and/or dietary
fiber consumption between low and high equol producers
(9,10,13,14). This study reveals that persons with a higher
PUFA and alcohol intake were more likely to be strong equol
producers. PUFA are concentrated in foods such as fish and
seafood, which are not generally consumed on a daily basis in
western countries (26). In Japan and Korea, however, the diet is
low in red meat and often rich in fish; thus, PUFA accounts for a
larger proportion of the total fat intake, which may explain why
the prevalence of strong equol producers is higher in these
countries (27). To our knowledge, the effect of alcohol on the gut
microbiota and, hence, their phytoestrogen metabolism, have
not been investigated directly. As it is rapidly and almost
completely absorbed in the stomach and the small intestine,
alcohol is not expected to importantly affect the intestinal
TABLE 2 Microbial and dietary variables in relation to the
in vivo equol producer phenotype1
In vivo equol producer
Characteristics Moderate (n ¼ 21) Strong (n ¼ 18)
Microbial variables
Pulmonary methane excretion, ppm 0.497 (0.218–1.134) 0.645 (0.283–1.047)
Fecal microbiota, log10 cells/g
Bacteria 0.615 (0.223–1.694) 1.779 (0.681–4.647)
C. coccoides-E. rectale group 0.959 (0.540–1.704) 0.478 (0.256–0.893)*
Sulfate-reducing bacteria 1.008 (0.858–1.184) 1.158 (0.971–1.380)*
Methanogens 0.833 (0.592–1.171) 1.036 (0.700–1.535)
Bifidobacteria 1.164 (0.270–5.018) 2.272 (0.408–12.663)
Dietary variables
Fat consumption, g/d
Total fat 0.863 (0.392–1.900) 0.718 (0.343–1.504)
SFA 1.080 (0.456–2.556) 1.316 (0.597–2.901)
MUFA 1.321 (0.482–3.617) 1.362 (0.515–3.602)
PUFA 1.163 (0.556–2.531) 2.150 (1.058–4.371)*
Fiber consumption, g/d 1.016 (0.929–1.110) 1.014 (0.910–1.129)
Fat:fiber ratio 1.635 (1.038–2.576) 0.582 (0.290–1.167)
Alcohol consumption, g/d 1.583 (0.965–2.598) 1.166 (0.721–1.887)*
1 Values are OR (95% CI) derived from nominal logistic regression with poor in vivo
equol producers, n ¼ 61, as reference category. *P # 0.050.
TABLE 3 Microbial and dietary variables in relation to the
in vitro equol producer phenotype1
In vitro equol producer
Characteristics Moderate (n ¼ 10) Strong (n ¼ 39)
Microbial variables
Pulmonary methane excretion, ppm 0.459 (0.147-1.435) 0.874 (0.460-1.659)
Fecal microbiota, log10 cells/g
Bacteria 1.227 (0.181-8.315) 1.466 (0.675-3.182)
C. coccoides-E. rectale group 1.018 (0.443-2.337) 0.576 (0.350-0.949*
Sulfate-reducing bacteria 0.876 (0.670-1.144) 1.156 (1.007-1.327)*
Methanogens 1.528 (0.577-4.043) 1.279 (0.911-1.796)
Bifidobacteria 5.602 (0.378-83.029) 2.051 (0.513-8.202)
Dietary variables
Fat consumption, g/d
Total fat 0.343 (0.113-1.044) 0.572 (0.305-1.070)
SFA 3.295 (0.976-11.126) 1.856 (0.938-3.670)
MUFA 3.595 (0.864-14.957) 1.790 (0.800-4.006)
PUFA 3.003 (1.097-8.223)* 2.131 (1.144-3.967)*
Fiber consumption, g/d 0.914 (0.796-1.050) 0.936 (0.857-1.021)
Fat:fiber ratio 1.153 (0.629-2.113) 0.797 (0.517-1.231)
Alcohol consumption, g/d 1.341 (0.717-2.506) 1.850 (1.215-2.817)*
1 Values are OR (95% CI) derived from nominal logistic regression with poor in vitro
equol producers, n ¼ 51, as reference category. *P , 0.050.
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bacteria, although alcohol consumption has been negatively as-
sociated with the microbial O-demethylation of isoxanthohumol,
a weak phytoestrogen present in hop-derived food supplements
and beers (15). No differences were found in the intake of
dietary fiber or the use of pre-, pro-, or synbiotic preparations. It
was previously shown in several dietary intervention studies that
the equol production could not be stimulated with fibers, pre-, or
probiotics (28–30).
In summary, we found that the bioavailability of genistein
and daidzein, estimated as the dose-percentages recovered in
24-h urine samples, was higher following soymilk consumption
than soy germ ingestion. The proportion equol:(daidzein 1
metabolites) excreted did not differ between the treatment
groups. However, differences in specific microbial and dietary
factors could be linked to the variation in equol production in
vivo and in vitro. Finally, both the equol production and the
phenotyping of the subjects based on the daidzein metabolism
by fecal cultures correlated well with those estimated from
the urinary excretion profiles, showing the potential of fecal
incubations to identify equol producers without dietary inter-
vention.
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